NCT06972732 - A Phase IV Clinical Trial to Compare the Efficacy and Safety of Metformin+Sodium-Glucose Cotransporter 2 Inhibitor(SGLT2-i)+Thiazolidinedione (TZD) in Patients With Type 2 Diabetes | Biotech Hunter

Enrollment

204

Participants

Timeline

Start Date

June 11, 2025

Primary Completion Date

October 1, 2026

Study Completion Date

October 1, 2026

Conditions

Type 2 Diabetes

Interventions

DRUG

Metformin

The dosage and dose frequency are maintained as they were before the screening.

DRUG

Dapagliflozin/Pioglitazone

Dapagliflozin 10mg/Pioglitazone 30mg QD

DRUG

Dapagliflozin/Sitagliptin

Dapagliflozin 10mg/Sitagliptin 100mg QD

Trial Locations (1)

RECRUITING

The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul